NORD

Nord Anglia Education, Inc.

NORD

Delisted

NORD was delisted on the 1st of September, 2017.

Back to rankings

Consumer Staples Education & Training Services

Financial journalist opinion

Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors

Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that Henrik Keller resigned from the Board of Directors (the “Board”) of Nordicus to pursue other interests; that the Board has been increased from three to five members; and that Torben Jensen, Kim T. Mücke and Andrew J. Ritter have been appointed to fill the vacancies on the Board.

Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors

Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia

BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces it has received positive and constructive feedback from the Danish Medicine Agency (“DKMA”) for its lead drug candidate, QR-02 for the treatment of oral leukoplakia.

Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia

Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs

BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced positive efficacy results for its lead periodontitis candidate, QR-01, in a preclinical study involving dogs diagnosed with periodontitis.

Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs

Orocidin and Syngene Partner to Accelerate Biotech Innovation

BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces a strategic partnership with Syngene International Limited (“Syngene”),

Orocidin and Syngene Partner to Accelerate Biotech Innovation

Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study

BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has successively completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.

Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia

BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces the groundbreaking development of QR-02, a unique and proprietary oral topical treatment designed to address oral leukoplakia with moderate to severe dysplasia, a potentially precancerous condition affecting millions worldwide.

Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia

Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment

BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has developed a novel, proprietary dental gel that represents a significant breakthrough in the long-term treatment of periodontitis.

Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment

Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis

BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced today that its subsidiary, Orocidin A/S, will initiate its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to conclude by the third quarter of 2025, paving the way for Orocidin to launch its first pilot efficacy study in patients by the end of 2025.

Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis

Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

BEVERLY HILLS, California, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced that its two wholly-owned subsidiaries, Orocidin A/S (“Orocidin”) and Bio-Convert ApS (“Bio-Convert”), expect to begin pilot efficacy studies in patients with periodontitis and oral leukoplakia in 2025. As of today both Orocidin and Bio-Convert are preclinical phase biopharmaceutical companies, which was incorrectly stated in previous press releases.

Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

NORDICUS now trading under symbol NORD

BEVERLY HILLS, California, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced FINRA has removed the appending "D" to the root symbol of its OTC equity symbol after the 20-day transition period subject to its reverse split with a CUSIP change announced on November 7, 2024.

NORDICUS now trading under symbol NORD

See News Rankings

Charts implemented using Lightweight Charts™